Amgen Inc. (AMGN) has recently been making news primarily due to its financial performance. The company has reported Q1 2025 earnings beating estimates and showing a considerable increase in revenue, reaching $8 billion. These results demonstrate a strong financial position, despite facing a $407 million antitrust verdict. Several asset management companies have made significant investments in Amgen, underscoring the stock's attractive prospects. However, some entities, such as Polar Capital Holdings Plc and NorthRock Partners LLC, have reduced their holdings. Amid a domestic manufacturing boom, questions are arising as to whether Amgen could be the best pharma stock to invest in. Furthermore, it seems unlikely that the CEO will see a significant pay rise this year. While AMGN stock has seen intermittent drops and has been downgraded by some analysts, it is generally considered a strong value stock. Additionally, the company is set to expand its manufacturing plant in Ohio, involving a hefty investment of $900 million. Amgen has also made strides in the bio-pharmaceutical industry, with its obesity drug moving closer to market entry and the FDA approving its therapy, Uplizna, for an autoimmune disorder.
Amgen AMGN News Analytics from Tue, 14 Jan 2025 08:00:00 GMT to Sat, 17 May 2025 19:30:53 GMT -
Rating 7
- Innovation 4
- Rumor -3
